You are here

  • Home
  • Archive
  • Volume 7, Issue 2
  • Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

Article metrics

Article menu

Download PDFPDF

XML
Psoriatic arthritis
Original research
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

 

Online download statistics by month:

Online download statistics by month: May 2021 to December 2022

AbstractFullPdf
May 2021299292146
Jun 202121820998
Jul 2021949235
Aug 2021706532
Sep 2021797737
Oct 2021918991
Nov 2021545129
Dec 2021494310
Jan 2022454221
Feb 2022575332
Mar 2022647136
Apr 2022616030
May 2022757434
Jun 2022525327
Jul 2022636321
Aug 2022555729
Sep 2022727324
Oct 2022777729
Nov 2022494816
Dec 2022323218
Total16561621795